ALLMedicine™ Poxviruses Center

May 12th, 2022 - Poxvirus proteins remodel signaling throughout the cell by targeting host enzymes for inhibition and redirection. Recently, it was discovered that early in infection the vaccinia virus (VACV) B12 pseudokinase copurifies with the cellular kinase VR...

Apr 12th, 2022 - Vaccinia virus (VV), the prototypic poxvirus, encodes a repertoire of proteins responsible for the metabolism of its large dsDNA genome. Previous work has furthered our understanding of how poxviruses replicate and recombine their genomes, but lit...

Jan 21st, 2022 - SAMD9 and SAMD9L (SAMD9/9L) are antiviral factors and tumor suppressors, playing a critical role in innate immune defense against poxviruses and the development of myeloid tumors. SAMD9/9L mutations with a gain-of-function (GoF) in inhibiting cell...

Sep 25th, 2021 - Many poxviruses produce proteins that are related to epidermal growth factor (EGF). Prior genome sequencing of ectromelia virus revealed a gene predicted to produce a protein with homology to EGF, which we refer to as ectromelia growth factor (ECG...

Aug 16th, 2021 - Poxviruses within the Capripoxvirus, Orthopoxvirus, and Parapoxvirus genera can infect livestock, with the two former having zoonotic importance. In addition, they induce similar clinical symptoms in common host species, creating a challenge for d...

Aug 12th, 2021 - Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and at present with no approved or proven antiviral treatment. Imatinib is a tyrosine kinase inhibitor th...

Sep 19th, 2017 - A phase 3 clinical trial of the experimental prostate cancer therapy rilimogene (Prostvac, Bavarian Nordic) has ended because the product did not meet interim efficacy goals, the company announced last week. The data and decision are a blow for Pr...

Sep 19th, 2017 - A phase 3 clinical trial of the experimental prostate cancer therapy rilimogene (Prostvac, Bavarian Nordic) has ended because the product did not meet interim efficacy goals, the company announced last week. The data and decision are a blow for Pr...

Jul 23rd, 2012 - Nancy E. Davidson, MD Director University of Pittsburgh Cancer Institute, UMPC Cancer Center Pittsburgh, PA While ovarian cancer survival rates have improved slightly since the 1970s, the overall five-year survival for patients diagnosed with the ...